Today, XtalPi, driven by AI and robotics for new drug and new material R&D (2228.HK) announced that its AI innovation R&D platform has successfully developed twoTargeted atInnovative Topical Efficacy Ingredients for Hair Growth and Strengthening ——Small Molecule Remeanagen™(XTP-118) andPeptide AquaKine™(XTP-016), the combination formula of these "twin molecules" has been verified for efficacy in multiple dimensions.It has demonstrated unique advantages in terms of efficacy, safety, and rapid onset.Both molecules have successfully been registered in the International Nomenclature of Cosmetic Ingredients (INCI). Their combined formulation has completed Facility Registration and Product Listing with the U.S. Food and Drug Administration (FDA) by Groland, a consumer brand incubated by XtalPi, and is set to launch in overseas markets. Meanwhile, the relevant ingredients are accelerating the completion of raw material filing in China.
Currently, hair loss hasBecoming a global challenge. According to statistics, the population affected by hair loss globally has exceeded 2.5 billion.，And continues to increase, with the number of people suffering from hair loss in China reaching 250 million., and the trend of younger patients is significant —— surveys show that in 2024, post-80s and post-90s generations account for over 70% of China's hair loss population. Facing this long-standing biomedical challenge of hair loss, the consumer market has long lacked truly safe, efficient, fast-acting, and widely applicable solutions. Existing products often suffer from unclear mechanisms of action, commonly presenting multiple pain points, including low user response rates, the risk of initial worsening of hair loss, and side effects such as hormonal imbalances caused by poor metabolism in the body.In response to the above challenges, XtalPi, originating from MIT, leverages leading AI + robotic molecular R&D capabilities to directly target the core biological pathways of abnormal hair loss.And deeply explore the key biomarkers for the full growth cycle of hair., the development of small molecule Remeanagen™ and polypeptide AquaKine™, two innovative maintenance ingredients, forms a synergistic formula, bringing a comprehensive upgrade in scalp care and anti-hair loss effects. It is expected to offer an efficient and safe new choice for the vast hair loss population globally, demonstrating huge market potential.
![]()
![]()
Cracking the Three Core Problems of Hair Care:
XtalPi's Path of Innovation
The core difficulty in hair regeneration lies in the complexity of molecular design, which needs to efficiently penetrate the skin barrier, precisely activate dormant hair follicles, and continuously optimize the microenvironment for hair growth with proper nutrition. The core advantage of XtalPi's AI platform is its ability to conduct precise molecular design for complex targets and efficiently iterate and optimize. Based on this platform capability, XtalPi has achieved breakthrough innovation, addressing the three key challenges in promoting and maintaining hair growth:
● 1. "Permeation": Breaking Through Barriers for Efficient Delivery
The first major challenge for topically applied functional products is penetrating the scalp's stratum corneum. Without effective transdermal absorption, all claims of efficacy are meaningless. XtalPi's AI platform has participated in uniquely challenging drug development projects, such as designing highly permeable peptides for eczema medications, accumulating extensive experience and methodologies. These can specifically optimize molecular permeability, enabling Remeanagen™ and AquaKine™ to achieve skin absorption efficiency far surpassing that of ordinary ingredients, laying a solid foundation for the full realization of subsequent efficacy.● 2."Stimulate": Awaken Dormant Seeds, Nurture at the Source to Prevent SheddingRemeanagen™ (XTP-118) is a model outcome of AI exploring unknown chemical space. XtalPi utilized its information mining platform, Patsight™, to lock on to key biological targets and designed innovative small molecule structures unimaginable to human chemists through AI screening, unlocking crucial biological functions.RemeanaThe core mechanism of gen™ lies in effectively activating dormant hair follicle stem cells, prompting them to re-enter the growth phase and significantly extending this cycle.1. Fluorescence contrast experiments and user cases clearly demonstrate its ability to activate and improve the healthy growth state of the scalp, achieving fullness and preventing hair loss at the source.2During the testing period, several middle-aged and elderly subjects who had been bald for many years grew new hair in a short term.3。● 3. "Nourish": Nourishing the fertile ground for growth, consolidating lush and abundant hairAfter re-entering the growth phase, the long-term health of hair follicles requires optimal microenvironment support. The XtalPi AI platform has designed the peptide molecule AquaKine™ (XTP-016) for the full hair growth cycle.AquaKine™ By acting on multiple key biomarkers in the hair growth cycle，Significantly improve the follicle microenvironment, including promoting the environment for collagen and elastin generation, and enhancing the proliferation environment of follicle keratinocytes and stem cells.4This effect directly enhances the health and nutritional supply of hair follicles, akin to fertilizing and strengthening the roots. It can effectively reduce hair loss, consolidate existing hair, and provide strong support for the growth of new hair."Permeate-Stimulate-Nourish" Triple Synergistic MechanismMaking this pair of "twin" moleculesNot only can it revitalize hair follicles and promote thickening at the source, but it can also consolidate existing hair, significantly improving hair density and quality to achieve the dual effects of fullness and hair strengthening.
Note: Data sourced from test results of third-party experimental institutions; effects may vary from person to person.
Excellent Validation: Significant Efficacy and High Safety
Tested for human efficacy by professional testing institutions, and undergone large-scale consumer-level real-use testing of the brand's formula for over half a year.5XtalPi's innovative "Gemini" molecules demonstrate outstanding performance, fully validating its product competitive advantages in terms of rapid onset, significant efficacy, and high safety.• Rapid onset:The study showed that the subjects were fastest inAfter 14 Days of UseThe preliminary effect of increased hair follicle density during the growth phase can be observed.6, rapid onset of action。
• Significant effects:After 45 days of use,Over 90% of subjects observed a visibly increased hair density.7; The average of the subjectsHair loss reduced by 33% to 45%8Among them, the transformation of a Level 4 hair loss subject who responded poorly to existing mainstream hair growth ingredients was quite representative — within 20 days, fine downy hair had grown on their scalp and gradually transformed into stronger, more mature hair.9。Note: Data sourced from test results of third-party experimental institutions; effects may vary from person to person.• High Safety:Particularly important is that the formula demonstrates excellent safety performance. The product development underwent a rigorous screening and verification process, ensuring safe and reliable long-term use. In a series of human efficacy tests10 In nearly a hundred real-world use cases, there were no adverse reactions such as the initial exacerbation of hair loss commonly seen in existing similar products.11; Thanks to its excellent water solubility and outstanding biocompatibility, the formulation is mild and non-irritating, offering a comfortable and burden-free experience.Note: Data sourced from third-party laboratories and testing institutions.
![]()
![]()
Strong Endorsement: A Decade-Honed AI R&D Engine
Remeanagen™、AquaKine™ The birth of two highly effective hair growth molecules was no accident. Behind them is XtalPi's AI molecular development platform ID4, which was built with an investment of billions of yuan over a decade and has been continuously optimized. The platform integrates a series of algorithmic innovations, and its molecular discovery and rational design capabilities have been repeatedly validated in practice. The ID4 platform also empowered Pfizer to rapidly develop the anti-COVID oral drug Paxlovid.®, contributing to the resolution of the global pandemic crisis. Relying on this platform, XtalPi has signed high-value collaborations with Eli Lilly for AI small molecule and AI biologics research, aiding Eli Lilly in tackling highly challenging drug targets. This platform also assisted innovative biotech company Signet Therapeutics in developing the breakthrough diffuse gastric cancer candidate drug SIGX1094, which received a nomination for the biopharmaceutical "Nobel Prize" – the Prix Galien USA Award. It is the powerful molecular prediction, design, and optimization capabilities of the ID4 platform that artfully address multiple challenges in the development of new hair growth ingredients, turning seemingly "impossible" new hair growth molecules into reality.
![]()
![]()
Business Model: Empower Partners, Create and Win Together
As XtalPi's first consumer product project, Remeanagen™ and AThe successful development of quaKine™ is strategically significant. The company has chosen to collaborate with a small technology firm listed on the Hong Kong stock market to advance this project.InnovationSuccessThe commercialization process of the成果. This collaboration not only demonstrates the strong empowerment value of XtalPi's platform for small and medium-sized enterprises, helping them achieve technological leaps and market value growth, but also ensures that Chinese consumers can experience cutting-edge innovations from local sources第一时间.
At the same time, this business model has the potential to bring higher commercial returns to innovators. Compared with the single-digit commercialization sharing ratio of traditional large pharmaceutical companies, XtalPi, as the holder of molecular IP,This time, it will enjoy a sales share of up to double-digit percentages., providing ample cash flow support for the subsequent development of more consumer health-related new products.
![]()
![]()
A New Era Begins: AI Molecules Benefit People's Livelihood
As Remeanagen™ and AquaKine™ have obtained key international authoritative certifications and are about to hit the market, XtalPi has officially ushered in a new era of its AI platform's dual-track driven strategy:Tackling the R&D of drugs for major diseases while creating consumer-level solutions to improve the daily quality of life for the masses.
This also endows XtalPi with a brand-new mission:
Let AI flow into every new drug;
Also let AI molecules enter everyone's wonderful life.
Note:
*The formula ingredients mentioned in the text cannot replace medications.
1. Data source: Groland brand and partner laboratories.2. Data source: Groland brand and theTest results of ROS fluorescence testing for the patented brand ingredient Remeanagen™ by a third-party laboratory.3、6、7、8, 11. Data SourceGroland Brand，99 subjects aged 18-70 with hair loss concerns used the Groland product twice daily, in the morning and evening, for 4 consecutive weeks. Self-assessment results were recorded at key intervals of 1 week, 2 weeks, 3 weeks, and 4 weeks. Some users completed a 6-month follow-up period, with actual effects varying from person to person.4. Data source: Experiments from Groland brand laboratories and third-party institutions on the brand's patented ingredients.Test Results of AquaKine™'s Multiple Collagen-Stimulating Effects.5. All consumer product use tests were completed within the approved usage scope of the product.9, 10. Data sourced from the Groland brand and third-party testing institutions, 32 individuals aged 28-59.Subjects with hair loss concerns used the raw material ingredients twice a day for 2 weeks, followed by instrument evaluation.Self-AssessmentAs a result, the actual effect varies from person to person.
![]()
![]()
